Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Dr. Arkady Mandel DSc., M.D., Ph.D.

Market Cap

75.78 Million CAD

Sector

Healthcare

Website

https://www.theralase.com

Description

Theralase Technologies Inc.

Read More

Overview

Value

1

Growth

41

Health

51

Management

60

Analyst Opinion

57

Total

42

All Scores Out Of 100

Best Features

  • Has a low level of debt
  • Low risk of bankruptcy
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • Income is not covering expenditure and investment
  • Earnings are negative
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Cashflow is growing faster than revenue

Market Peers

TLT.V

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

-137.14%

Revenue Growth (5 Year Average)

-9.41%

Ratings Consensus

Neutral

Share Buybacks

-16.11%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

1

  • Estimated intrinsic-value of NaN undefined CAD is lower than current price ( 350.00 undefined CAD)
  • Free-cashflow-yeild of -7.01% is worse than the market average (4.7%)
  • Margin-of-safety of -137.14% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 0.4 CAD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-7.01%

PE/Earnings Growth

N/A

Price/Book

20.72x

Growth

Growth Score

41

  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 18.56% is higher than the market average (14.48%)
  • 5 Year Average Cashflow growth of 14.71% is higher than the market average (12.35%)
  • 5 Year Average Revenue growth of -9.41% is lower than the market average (10.97%)
  • Earnings growth has slowed this year
  • Free Cashflow growth has slowed this year

Revenue Growth

-9.41%

Earnings Growth

18.56%

Cashflow Growth

14.71%

Health

Health Score

51

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Debt repayments significantly impact cashflow

Altman Z Score

20.00

Piostroski Score

3.00

Debt/Equity

0.01x

Current Assets/Liabilities

5.71x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.01x

Management

Management Score

60

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -56.50% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -93.94% is lower than the market average (15%)

Average Buybacks/Dilution

-16.11%

Recent Buybacks/Dilution

5.99%

5 Year Price Volitility

30.35%

Return On Assets

-80.12%

Return On Capital Employed

-56.50%

Return On Equity

-93.94%

Return On Free Cashflow

103.30%

Return On Investments

N/A

Analysts

Analyst Opinion

57

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Theralase Technologies Inc.

Currency

CAD

Beta

1.95238

Vol Avg

77937

Ceo

Dr. Arkady Mandel DSc., M.D., Ph.D.

Cik

Cusip

Exchange

TSXV

Full Time Employees

Industry

Medical Devices

Sector

Healthcare

Ipo Date

Address

41 Hollinger Road

City

Toronto

State

ON

Country

CA

Zip

M4B 3G4

Phone

416 699 5273

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies